Tumor angiogenesis - Columbia University › sites › default › files › JK2015pdf.pdf · Tumor...
Transcript of Tumor angiogenesis - Columbia University › sites › default › files › JK2015pdf.pdf · Tumor...
![Page 1: Tumor angiogenesis - Columbia University › sites › default › files › JK2015pdf.pdf · Tumor angiogenesis Jan Kitajewski ICRC 926, ph 851-4688, email: jkk9. Blood Vessel Development](https://reader033.fdocuments.in/reader033/viewer/2022053011/5f0e80177e708231d43f8c1a/html5/thumbnails/1.jpg)
BACKGROUND READING:
Tumor Angiogenesis- general “Angiogenesis in Cancer and other Diseases” Peter Carmeliet and Rakesh Jain. Nature 407: 249-57 (2000)
Tumor Angiogenesis - therapeutics “Vascular Endothelial Growth Factor Signaling Pathways: Therapeutic Perspective” Marcin Kovanetz and Napoleone Ferrara. Clinical Cancer Research 12: 5018-22 (2006)
Notch in Tumor Angiogenesis ‘Notch signaling in developmental and tumor angiogenesis” Kofler NM, Shawber CJ, Kangsamaksin T, Reed HO, Galatioto J, Kitajewski J.
Genes Cancer. 2(12):1106-16. (2011)
Tumor angiogenesis
Jan Kitajewski ICRC 926, ph 851-4688, email: jkk9
![Page 2: Tumor angiogenesis - Columbia University › sites › default › files › JK2015pdf.pdf · Tumor angiogenesis Jan Kitajewski ICRC 926, ph 851-4688, email: jkk9. Blood Vessel Development](https://reader033.fdocuments.in/reader033/viewer/2022053011/5f0e80177e708231d43f8c1a/html5/thumbnails/2.jpg)
Blood Vessel Development
• Vasculogenesis = de novo tube formation
• Angiogenesis = sprouting of new tubes off of pre-existing tubes
• Cell types
Endothelial Cell = cell type that makes up and lines blood vessels
Mural Cells = specialized cells that surround blood vessels
• Pericytes
• Smooth muscle cells
• Angiogenic Factors
– Vascular Endothelial Growth Factor (VEGF-A, VEGF-B, PlGF, VEGF-C…..)
– Angiopoietins (Ang 1, Ang2, ………..)
– Notch ligands (Jagged1, Delta4)
![Page 3: Tumor angiogenesis - Columbia University › sites › default › files › JK2015pdf.pdf · Tumor angiogenesis Jan Kitajewski ICRC 926, ph 851-4688, email: jkk9. Blood Vessel Development](https://reader033.fdocuments.in/reader033/viewer/2022053011/5f0e80177e708231d43f8c1a/html5/thumbnails/3.jpg)
![Page 4: Tumor angiogenesis - Columbia University › sites › default › files › JK2015pdf.pdf · Tumor angiogenesis Jan Kitajewski ICRC 926, ph 851-4688, email: jkk9. Blood Vessel Development](https://reader033.fdocuments.in/reader033/viewer/2022053011/5f0e80177e708231d43f8c1a/html5/thumbnails/4.jpg)
Vessel structure Blood Vessel
Thin layer of endothelium with tight junctions
and well developed basement membrane.
Capillaries, venules, veins, arteries, arterioles
Arteries with multple layers of vascular smooth
muscle cells. Capillaries with sparse, loosely
attached pericytes
Lymphatic Vessel
Thin layer of endothelium with a poorly
developed basement membrane (BM) and
lacking pericytes (PC)
Endothelial cells (EC) overlap to form valves
that can open with increases in pressure to let in
fluid and immune cells
Blood and lymphatic vessels develop in an
overlapping pattern
Saharinen et al., Trends Immunol, 2004
![Page 5: Tumor angiogenesis - Columbia University › sites › default › files › JK2015pdf.pdf · Tumor angiogenesis Jan Kitajewski ICRC 926, ph 851-4688, email: jkk9. Blood Vessel Development](https://reader033.fdocuments.in/reader033/viewer/2022053011/5f0e80177e708231d43f8c1a/html5/thumbnails/5.jpg)
pericyte
Endothelial
cell
![Page 6: Tumor angiogenesis - Columbia University › sites › default › files › JK2015pdf.pdf · Tumor angiogenesis Jan Kitajewski ICRC 926, ph 851-4688, email: jkk9. Blood Vessel Development](https://reader033.fdocuments.in/reader033/viewer/2022053011/5f0e80177e708231d43f8c1a/html5/thumbnails/6.jpg)
Vascular Development
ANGIOGENESIS
Cellular steps in Angiogenesis
1) Biochemical Response and Preparation
2) Sprout initiation
3) Migration
4) Proliferation
5) Survival
6) Tube Formation
7) Maturation
8) Completion
9) Blood Flow
![Page 7: Tumor angiogenesis - Columbia University › sites › default › files › JK2015pdf.pdf · Tumor angiogenesis Jan Kitajewski ICRC 926, ph 851-4688, email: jkk9. Blood Vessel Development](https://reader033.fdocuments.in/reader033/viewer/2022053011/5f0e80177e708231d43f8c1a/html5/thumbnails/7.jpg)
Tip Cells
Stalk Cell
VEGF
Lumen
![Page 8: Tumor angiogenesis - Columbia University › sites › default › files › JK2015pdf.pdf · Tumor angiogenesis Jan Kitajewski ICRC 926, ph 851-4688, email: jkk9. Blood Vessel Development](https://reader033.fdocuments.in/reader033/viewer/2022053011/5f0e80177e708231d43f8c1a/html5/thumbnails/8.jpg)
VEGF and VEGF Receptors
Blood
Endothelial
Cell
Lymphatic
Endothelial
Cell
![Page 9: Tumor angiogenesis - Columbia University › sites › default › files › JK2015pdf.pdf · Tumor angiogenesis Jan Kitajewski ICRC 926, ph 851-4688, email: jkk9. Blood Vessel Development](https://reader033.fdocuments.in/reader033/viewer/2022053011/5f0e80177e708231d43f8c1a/html5/thumbnails/9.jpg)
VEGF-receptor
signaling
Promotes:
Proliferation
Migration
Survival
![Page 10: Tumor angiogenesis - Columbia University › sites › default › files › JK2015pdf.pdf · Tumor angiogenesis Jan Kitajewski ICRC 926, ph 851-4688, email: jkk9. Blood Vessel Development](https://reader033.fdocuments.in/reader033/viewer/2022053011/5f0e80177e708231d43f8c1a/html5/thumbnails/10.jpg)
Angiogenesis - Basement Membrane Breakdown
Smooth Muscle
Cells
Endothelium
Basement
Membrane
Proteases
Angiogenic
Stimulus
(VEGF)
![Page 11: Tumor angiogenesis - Columbia University › sites › default › files › JK2015pdf.pdf · Tumor angiogenesis Jan Kitajewski ICRC 926, ph 851-4688, email: jkk9. Blood Vessel Development](https://reader033.fdocuments.in/reader033/viewer/2022053011/5f0e80177e708231d43f8c1a/html5/thumbnails/11.jpg)
Angiogenesis - Endothelial Cell Migration
Endothelium
Nascent
Vascular Sprouts
VEGF
Smooth Muscle
Cells
Basement
Membrane
![Page 12: Tumor angiogenesis - Columbia University › sites › default › files › JK2015pdf.pdf · Tumor angiogenesis Jan Kitajewski ICRC 926, ph 851-4688, email: jkk9. Blood Vessel Development](https://reader033.fdocuments.in/reader033/viewer/2022053011/5f0e80177e708231d43f8c1a/html5/thumbnails/12.jpg)
Notch drives cell fate determination
Notch/Notch ligand interaction:
-mechanism for setting and maintaining state of differentiation
-fates locked in via lateral inhibition
Notch signaling is a mechanism for defining tip versus tube cell during sprouting angiogenesis
![Page 13: Tumor angiogenesis - Columbia University › sites › default › files › JK2015pdf.pdf · Tumor angiogenesis Jan Kitajewski ICRC 926, ph 851-4688, email: jkk9. Blood Vessel Development](https://reader033.fdocuments.in/reader033/viewer/2022053011/5f0e80177e708231d43f8c1a/html5/thumbnails/13.jpg)
Notch drives cell fate differentiation
Notch/Notch ligand interaction:
-mechanism for driving state of differentiation
-fates locked in via lateral inhibition
Notch
Notch ligand
![Page 14: Tumor angiogenesis - Columbia University › sites › default › files › JK2015pdf.pdf · Tumor angiogenesis Jan Kitajewski ICRC 926, ph 851-4688, email: jkk9. Blood Vessel Development](https://reader033.fdocuments.in/reader033/viewer/2022053011/5f0e80177e708231d43f8c1a/html5/thumbnails/14.jpg)
Notch drives cell fate differentiation
Notch/Notch ligand interaction:
-mechanism for driving state of differentiation
-fates locked in via lateral inhibition
![Page 15: Tumor angiogenesis - Columbia University › sites › default › files › JK2015pdf.pdf · Tumor angiogenesis Jan Kitajewski ICRC 926, ph 851-4688, email: jkk9. Blood Vessel Development](https://reader033.fdocuments.in/reader033/viewer/2022053011/5f0e80177e708231d43f8c1a/html5/thumbnails/15.jpg)
Notch drives cell fate differentiation
Notch/Notch ligand interaction:
-mechanism for driving state of differentiation
-fates locked in via lateral inhibition
Notch Notch ligand
Notch ON Notch OFF
![Page 16: Tumor angiogenesis - Columbia University › sites › default › files › JK2015pdf.pdf · Tumor angiogenesis Jan Kitajewski ICRC 926, ph 851-4688, email: jkk9. Blood Vessel Development](https://reader033.fdocuments.in/reader033/viewer/2022053011/5f0e80177e708231d43f8c1a/html5/thumbnails/16.jpg)
Notch drives cell fate differentiation
Notch/Notch ligand interaction:
-mechanism for driving state of differentiation
-fates locked in via lateral inhibition
Notch Notch ligand
Notch ON Notch OFF
Notch blocks sprout initiation
Stalk Tip
![Page 17: Tumor angiogenesis - Columbia University › sites › default › files › JK2015pdf.pdf · Tumor angiogenesis Jan Kitajewski ICRC 926, ph 851-4688, email: jkk9. Blood Vessel Development](https://reader033.fdocuments.in/reader033/viewer/2022053011/5f0e80177e708231d43f8c1a/html5/thumbnails/17.jpg)
Notch drives cell fate differentiation
Notch/Notch ligand interaction:
-mechanism for driving state of differentiation
-fates locked in via lateral inhibition
Notch Notch ligand
Notch OFF Notch OFF
Notch blockade causes sprout initiation
Stalk Tip
![Page 18: Tumor angiogenesis - Columbia University › sites › default › files › JK2015pdf.pdf · Tumor angiogenesis Jan Kitajewski ICRC 926, ph 851-4688, email: jkk9. Blood Vessel Development](https://reader033.fdocuments.in/reader033/viewer/2022053011/5f0e80177e708231d43f8c1a/html5/thumbnails/18.jpg)
Notch
Dll4
VEGFR-2
VEGFR-1
VEGFR-2
VEGF
![Page 19: Tumor angiogenesis - Columbia University › sites › default › files › JK2015pdf.pdf · Tumor angiogenesis Jan Kitajewski ICRC 926, ph 851-4688, email: jkk9. Blood Vessel Development](https://reader033.fdocuments.in/reader033/viewer/2022053011/5f0e80177e708231d43f8c1a/html5/thumbnails/19.jpg)
Wild-type Notch Mutant (Notch1 +/-)
Notch functions
to restrict sprouting
in retinal angiogenesis
![Page 20: Tumor angiogenesis - Columbia University › sites › default › files › JK2015pdf.pdf · Tumor angiogenesis Jan Kitajewski ICRC 926, ph 851-4688, email: jkk9. Blood Vessel Development](https://reader033.fdocuments.in/reader033/viewer/2022053011/5f0e80177e708231d43f8c1a/html5/thumbnails/20.jpg)
Angiogenesis - Endothelial Cell Proliferation
Endothelium
VEGF
Sprout
Elongation Smooth Muscle
Cells
Basement
Membrane
![Page 21: Tumor angiogenesis - Columbia University › sites › default › files › JK2015pdf.pdf · Tumor angiogenesis Jan Kitajewski ICRC 926, ph 851-4688, email: jkk9. Blood Vessel Development](https://reader033.fdocuments.in/reader033/viewer/2022053011/5f0e80177e708231d43f8c1a/html5/thumbnails/21.jpg)
Angiogenesis - Capillary Morphogenesis
Endothelium
VEGF
New
Lumen
Formation Smooth Muscle
Cells
Basement
Membrane
![Page 22: Tumor angiogenesis - Columbia University › sites › default › files › JK2015pdf.pdf · Tumor angiogenesis Jan Kitajewski ICRC 926, ph 851-4688, email: jkk9. Blood Vessel Development](https://reader033.fdocuments.in/reader033/viewer/2022053011/5f0e80177e708231d43f8c1a/html5/thumbnails/22.jpg)
Angiogenesis - Vascular Maturation
Endothelium
VEGF
Vascular Pruning
(apoptosis?)
SMC, pericyte
recruitment
Smooth Muscle
Cells
Basement
Membrane
![Page 23: Tumor angiogenesis - Columbia University › sites › default › files › JK2015pdf.pdf · Tumor angiogenesis Jan Kitajewski ICRC 926, ph 851-4688, email: jkk9. Blood Vessel Development](https://reader033.fdocuments.in/reader033/viewer/2022053011/5f0e80177e708231d43f8c1a/html5/thumbnails/23.jpg)
Angiogenesis - Vascular Maturation
Endothelium
VEGF
Endothelial
cell-cell junctions
Smooth Muscle
Cells
Basement
Membrane
Negative
Feedback
![Page 24: Tumor angiogenesis - Columbia University › sites › default › files › JK2015pdf.pdf · Tumor angiogenesis Jan Kitajewski ICRC 926, ph 851-4688, email: jkk9. Blood Vessel Development](https://reader033.fdocuments.in/reader033/viewer/2022053011/5f0e80177e708231d43f8c1a/html5/thumbnails/24.jpg)
![Page 25: Tumor angiogenesis - Columbia University › sites › default › files › JK2015pdf.pdf · Tumor angiogenesis Jan Kitajewski ICRC 926, ph 851-4688, email: jkk9. Blood Vessel Development](https://reader033.fdocuments.in/reader033/viewer/2022053011/5f0e80177e708231d43f8c1a/html5/thumbnails/25.jpg)
![Page 26: Tumor angiogenesis - Columbia University › sites › default › files › JK2015pdf.pdf · Tumor angiogenesis Jan Kitajewski ICRC 926, ph 851-4688, email: jkk9. Blood Vessel Development](https://reader033.fdocuments.in/reader033/viewer/2022053011/5f0e80177e708231d43f8c1a/html5/thumbnails/26.jpg)
![Page 27: Tumor angiogenesis - Columbia University › sites › default › files › JK2015pdf.pdf · Tumor angiogenesis Jan Kitajewski ICRC 926, ph 851-4688, email: jkk9. Blood Vessel Development](https://reader033.fdocuments.in/reader033/viewer/2022053011/5f0e80177e708231d43f8c1a/html5/thumbnails/27.jpg)
![Page 28: Tumor angiogenesis - Columbia University › sites › default › files › JK2015pdf.pdf · Tumor angiogenesis Jan Kitajewski ICRC 926, ph 851-4688, email: jkk9. Blood Vessel Development](https://reader033.fdocuments.in/reader033/viewer/2022053011/5f0e80177e708231d43f8c1a/html5/thumbnails/28.jpg)
![Page 29: Tumor angiogenesis - Columbia University › sites › default › files › JK2015pdf.pdf · Tumor angiogenesis Jan Kitajewski ICRC 926, ph 851-4688, email: jkk9. Blood Vessel Development](https://reader033.fdocuments.in/reader033/viewer/2022053011/5f0e80177e708231d43f8c1a/html5/thumbnails/29.jpg)
![Page 30: Tumor angiogenesis - Columbia University › sites › default › files › JK2015pdf.pdf · Tumor angiogenesis Jan Kitajewski ICRC 926, ph 851-4688, email: jkk9. Blood Vessel Development](https://reader033.fdocuments.in/reader033/viewer/2022053011/5f0e80177e708231d43f8c1a/html5/thumbnails/30.jpg)
![Page 31: Tumor angiogenesis - Columbia University › sites › default › files › JK2015pdf.pdf · Tumor angiogenesis Jan Kitajewski ICRC 926, ph 851-4688, email: jkk9. Blood Vessel Development](https://reader033.fdocuments.in/reader033/viewer/2022053011/5f0e80177e708231d43f8c1a/html5/thumbnails/31.jpg)
VEGF
VEGF is a hypoxia induced gene
![Page 32: Tumor angiogenesis - Columbia University › sites › default › files › JK2015pdf.pdf · Tumor angiogenesis Jan Kitajewski ICRC 926, ph 851-4688, email: jkk9. Blood Vessel Development](https://reader033.fdocuments.in/reader033/viewer/2022053011/5f0e80177e708231d43f8c1a/html5/thumbnails/32.jpg)
Angiogenic sprouting
Vessel Cooption
Models of Tumor Angiogenesis
![Page 33: Tumor angiogenesis - Columbia University › sites › default › files › JK2015pdf.pdf · Tumor angiogenesis Jan Kitajewski ICRC 926, ph 851-4688, email: jkk9. Blood Vessel Development](https://reader033.fdocuments.in/reader033/viewer/2022053011/5f0e80177e708231d43f8c1a/html5/thumbnails/33.jpg)
Multiple roles for VEGF
when do you need and when not?
![Page 34: Tumor angiogenesis - Columbia University › sites › default › files › JK2015pdf.pdf · Tumor angiogenesis Jan Kitajewski ICRC 926, ph 851-4688, email: jkk9. Blood Vessel Development](https://reader033.fdocuments.in/reader033/viewer/2022053011/5f0e80177e708231d43f8c1a/html5/thumbnails/34.jpg)
Lymphangiogenic VEGF Receptors promote tumor lymphangiogenesis and lymph node metastasis
![Page 35: Tumor angiogenesis - Columbia University › sites › default › files › JK2015pdf.pdf · Tumor angiogenesis Jan Kitajewski ICRC 926, ph 851-4688, email: jkk9. Blood Vessel Development](https://reader033.fdocuments.in/reader033/viewer/2022053011/5f0e80177e708231d43f8c1a/html5/thumbnails/35.jpg)
Structure of blood and lymphatic vasculature in dermis
normal + lymphatics - lymphatics
Mouse with mutation in VEGFR-3 blood vessel
lymphatic vessel
![Page 36: Tumor angiogenesis - Columbia University › sites › default › files › JK2015pdf.pdf · Tumor angiogenesis Jan Kitajewski ICRC 926, ph 851-4688, email: jkk9. Blood Vessel Development](https://reader033.fdocuments.in/reader033/viewer/2022053011/5f0e80177e708231d43f8c1a/html5/thumbnails/36.jpg)
Expression of Tag + VEGF-C
Tumor Lymphangiogenesis?
![Page 37: Tumor angiogenesis - Columbia University › sites › default › files › JK2015pdf.pdf · Tumor angiogenesis Jan Kitajewski ICRC 926, ph 851-4688, email: jkk9. Blood Vessel Development](https://reader033.fdocuments.in/reader033/viewer/2022053011/5f0e80177e708231d43f8c1a/html5/thumbnails/37.jpg)
![Page 38: Tumor angiogenesis - Columbia University › sites › default › files › JK2015pdf.pdf · Tumor angiogenesis Jan Kitajewski ICRC 926, ph 851-4688, email: jkk9. Blood Vessel Development](https://reader033.fdocuments.in/reader033/viewer/2022053011/5f0e80177e708231d43f8c1a/html5/thumbnails/38.jpg)
Inhibition of VEGF and VEGF Receptors
Avastin-humanized anti-VEGF Ab
anti-VEGF-R2 Ab anti-VEGF-R1 Ab
Soluble Flt-1
VEGF-TRAP
Chemical inhibitors
Of tryosine kinases
![Page 39: Tumor angiogenesis - Columbia University › sites › default › files › JK2015pdf.pdf · Tumor angiogenesis Jan Kitajewski ICRC 926, ph 851-4688, email: jkk9. Blood Vessel Development](https://reader033.fdocuments.in/reader033/viewer/2022053011/5f0e80177e708231d43f8c1a/html5/thumbnails/39.jpg)
![Page 40: Tumor angiogenesis - Columbia University › sites › default › files › JK2015pdf.pdf · Tumor angiogenesis Jan Kitajewski ICRC 926, ph 851-4688, email: jkk9. Blood Vessel Development](https://reader033.fdocuments.in/reader033/viewer/2022053011/5f0e80177e708231d43f8c1a/html5/thumbnails/40.jpg)
VEGF Trap (Regeneron)
case study
• Composite decoy receptor
• High affinity binding to all species of VEGF (Kd < 1 pM), half-life ~25 days
• Binds PlGF, VEGF-B
• Phase I clinical trials
![Page 41: Tumor angiogenesis - Columbia University › sites › default › files › JK2015pdf.pdf · Tumor angiogenesis Jan Kitajewski ICRC 926, ph 851-4688, email: jkk9. Blood Vessel Development](https://reader033.fdocuments.in/reader033/viewer/2022053011/5f0e80177e708231d43f8c1a/html5/thumbnails/41.jpg)
Anti-VEGF blockade
in
experimental Wilms Tumor
Study conducted by Drs. Jessica Kandel (Surgery), Darrell Yamashiro (Pediatrics
Oncology), Jay Huang (Surgery)
![Page 42: Tumor angiogenesis - Columbia University › sites › default › files › JK2015pdf.pdf · Tumor angiogenesis Jan Kitajewski ICRC 926, ph 851-4688, email: jkk9. Blood Vessel Development](https://reader033.fdocuments.in/reader033/viewer/2022053011/5f0e80177e708231d43f8c1a/html5/thumbnails/42.jpg)
Tumor regression schema:
• Tumors are implanted and allowed to grow for 6 weeks, at which point they are large (> 1 gm) and metastatic
• Treatment with VEGF Trap starts at Day 0
![Page 43: Tumor angiogenesis - Columbia University › sites › default › files › JK2015pdf.pdf · Tumor angiogenesis Jan Kitajewski ICRC 926, ph 851-4688, email: jkk9. Blood Vessel Development](https://reader033.fdocuments.in/reader033/viewer/2022053011/5f0e80177e708231d43f8c1a/html5/thumbnails/43.jpg)
VEGF-Trap regresses established
tumors
Huang et al, PNAS June 2003
![Page 44: Tumor angiogenesis - Columbia University › sites › default › files › JK2015pdf.pdf · Tumor angiogenesis Jan Kitajewski ICRC 926, ph 851-4688, email: jkk9. Blood Vessel Development](https://reader033.fdocuments.in/reader033/viewer/2022053011/5f0e80177e708231d43f8c1a/html5/thumbnails/44.jpg)
What happens if we continue to treat
regressed tumors?
• Tumors regressed by ~80% at day 36
![Page 45: Tumor angiogenesis - Columbia University › sites › default › files › JK2015pdf.pdf · Tumor angiogenesis Jan Kitajewski ICRC 926, ph 851-4688, email: jkk9. Blood Vessel Development](https://reader033.fdocuments.in/reader033/viewer/2022053011/5f0e80177e708231d43f8c1a/html5/thumbnails/45.jpg)
0 10 20 30 40 50 60 70 800
50
100
Days
Day 36
All tumors recur after initial
regression by VEGF Trap
![Page 46: Tumor angiogenesis - Columbia University › sites › default › files › JK2015pdf.pdf · Tumor angiogenesis Jan Kitajewski ICRC 926, ph 851-4688, email: jkk9. Blood Vessel Development](https://reader033.fdocuments.in/reader033/viewer/2022053011/5f0e80177e708231d43f8c1a/html5/thumbnails/46.jpg)
Block receptor activation
via presenilin
presenilin
GSI = gamma-secretase inhibitor
![Page 47: Tumor angiogenesis - Columbia University › sites › default › files › JK2015pdf.pdf · Tumor angiogenesis Jan Kitajewski ICRC 926, ph 851-4688, email: jkk9. Blood Vessel Development](https://reader033.fdocuments.in/reader033/viewer/2022053011/5f0e80177e708231d43f8c1a/html5/thumbnails/47.jpg)
-GSI inhibition of Notch is toxic to intestine
-gamma secretase inhibitor Dll4 inhibitor
![Page 48: Tumor angiogenesis - Columbia University › sites › default › files › JK2015pdf.pdf · Tumor angiogenesis Jan Kitajewski ICRC 926, ph 851-4688, email: jkk9. Blood Vessel Development](https://reader033.fdocuments.in/reader033/viewer/2022053011/5f0e80177e708231d43f8c1a/html5/thumbnails/48.jpg)
Dll4 blocking antibodies
Ridgway etal. Nature (2006) 444:1083.
Noguera-Troise etal. Nature (2006) 444:1032.
![Page 49: Tumor angiogenesis - Columbia University › sites › default › files › JK2015pdf.pdf · Tumor angiogenesis Jan Kitajewski ICRC 926, ph 851-4688, email: jkk9. Blood Vessel Development](https://reader033.fdocuments.in/reader033/viewer/2022053011/5f0e80177e708231d43f8c1a/html5/thumbnails/49.jpg)
Dll4 blockade induces excesses sprouting during retinal angiogenesis
Ridgway etal. Nature (2006) 444:1083.
![Page 50: Tumor angiogenesis - Columbia University › sites › default › files › JK2015pdf.pdf · Tumor angiogenesis Jan Kitajewski ICRC 926, ph 851-4688, email: jkk9. Blood Vessel Development](https://reader033.fdocuments.in/reader033/viewer/2022053011/5f0e80177e708231d43f8c1a/html5/thumbnails/50.jpg)
Dll4 blockade promotes dysfunctional sprouting
Ridgway etal. Nature (2006) 444:1083.
![Page 51: Tumor angiogenesis - Columbia University › sites › default › files › JK2015pdf.pdf · Tumor angiogenesis Jan Kitajewski ICRC 926, ph 851-4688, email: jkk9. Blood Vessel Development](https://reader033.fdocuments.in/reader033/viewer/2022053011/5f0e80177e708231d43f8c1a/html5/thumbnails/51.jpg)
Delta-like 4 as a therapeutic target in oncology
“The Dll4/Notch paradox” DLL4 blockade promote sprouting while blocking tumor growth
2008 - Regeneron (Yancapoulous & Thurston) / Genentech / Adrian Harris (Oxford)
overgrowth
dysfunctional vasculature
Inhibits tumor growth
![Page 52: Tumor angiogenesis - Columbia University › sites › default › files › JK2015pdf.pdf · Tumor angiogenesis Jan Kitajewski ICRC 926, ph 851-4688, email: jkk9. Blood Vessel Development](https://reader033.fdocuments.in/reader033/viewer/2022053011/5f0e80177e708231d43f8c1a/html5/thumbnails/52.jpg)
Case Study #2: Notch as a therapeutic target in Tumor Angiogenesis
Notch decoy: inhibitor of Notch signaling Yasuhiro Funahashi, Carrie Shawber, Jan Kitajewski
![Page 53: Tumor angiogenesis - Columbia University › sites › default › files › JK2015pdf.pdf · Tumor angiogenesis Jan Kitajewski ICRC 926, ph 851-4688, email: jkk9. Blood Vessel Development](https://reader033.fdocuments.in/reader033/viewer/2022053011/5f0e80177e708231d43f8c1a/html5/thumbnails/53.jpg)
control VEGF-A VEGF-A + N1ECD notch decoy
PECAM
Notch decoy & VEGF121 secreted from dermally implanted chamber
Notch decoy blocks VEGF-induced
dermal angiogenesis
![Page 54: Tumor angiogenesis - Columbia University › sites › default › files › JK2015pdf.pdf · Tumor angiogenesis Jan Kitajewski ICRC 926, ph 851-4688, email: jkk9. Blood Vessel Development](https://reader033.fdocuments.in/reader033/viewer/2022053011/5f0e80177e708231d43f8c1a/html5/thumbnails/54.jpg)
– Notch-based fusion proteins and uses thereof Patent no. 7,662,919
– Kitajewski
Fc
Fc
NOTCH1
EGF-like repeats 1-36 LNR TM ANK PEST
Fc
Anti- Jagged1/Dll4
Anti-Dll4
Anti-Jagged1
Fc1-1
3
10-24
1-24
0.0
0.5
1.0
1.5
2.0
2.5
Tu
mo
r W
eig
ht (
g)
* * *
Fc1-1
3
10-24
1-24
0.0
0.1
0.2
0.3
0.4
Tu
mo
r W
eig
ht (
g)
* *
Mm5MT-FGF4 KP1-VEGF
Fc1-
13
10-2
41-
240.0
0.1
0.2
0.3
0.4
0.5T
um
or W
eig
ht (
g)
* * *
Fc1-
13
10-24
1-24
-0.5
0.0
0.5
1.0
1.5
2.0
Tu
mo
r W
eig
ht (
g)
* * *
LLC B16-F10
![Page 55: Tumor angiogenesis - Columbia University › sites › default › files › JK2015pdf.pdf · Tumor angiogenesis Jan Kitajewski ICRC 926, ph 851-4688, email: jkk9. Blood Vessel Development](https://reader033.fdocuments.in/reader033/viewer/2022053011/5f0e80177e708231d43f8c1a/html5/thumbnails/55.jpg)
Anti-Angiogenic
Therapy in Humans
![Page 56: Tumor angiogenesis - Columbia University › sites › default › files › JK2015pdf.pdf · Tumor angiogenesis Jan Kitajewski ICRC 926, ph 851-4688, email: jkk9. Blood Vessel Development](https://reader033.fdocuments.in/reader033/viewer/2022053011/5f0e80177e708231d43f8c1a/html5/thumbnails/56.jpg)
Bevacizumab (Avastin) • Recombinant humanized monoclonal
IgG1 antibody derived from the murine VEGF-A monoclonal antibody A4.6.1
• Murine VEGF-binding residues (7% of protein sequence)
• Human IgG1 framework (93%)
• Binds all isoforms of human VEGF
• Binding affinity: Kd = 8 × 10–10 M
• Half-life 20 days
• First FDA approved anti-angiogeneic agent (approved in 2004)
Moen M. Drugs. 2010; 70(2):181-9.
Escudier B et al. Biologics. 2008; 2(3):517-530.
Avastin.com
![Page 57: Tumor angiogenesis - Columbia University › sites › default › files › JK2015pdf.pdf · Tumor angiogenesis Jan Kitajewski ICRC 926, ph 851-4688, email: jkk9. Blood Vessel Development](https://reader033.fdocuments.in/reader033/viewer/2022053011/5f0e80177e708231d43f8c1a/html5/thumbnails/57.jpg)
Bevacizumab in Colorectal Cancer
813 patients
Untreated mCRC
402 Chemo alone (IFL) qw
411 Chemo (IFL) + bev 5mg/kg q2w
Outcome:
Overall Survival
![Page 58: Tumor angiogenesis - Columbia University › sites › default › files › JK2015pdf.pdf · Tumor angiogenesis Jan Kitajewski ICRC 926, ph 851-4688, email: jkk9. Blood Vessel Development](https://reader033.fdocuments.in/reader033/viewer/2022053011/5f0e80177e708231d43f8c1a/html5/thumbnails/58.jpg)
Avastin = Bevacizamide = anti-VEGF-A Antibody (humanized)
Makes it way into the clinic- FDA approved 3/2004
Colorectal Cancer
![Page 59: Tumor angiogenesis - Columbia University › sites › default › files › JK2015pdf.pdf · Tumor angiogenesis Jan Kitajewski ICRC 926, ph 851-4688, email: jkk9. Blood Vessel Development](https://reader033.fdocuments.in/reader033/viewer/2022053011/5f0e80177e708231d43f8c1a/html5/thumbnails/59.jpg)
• VEGF pathway
– Approved drugs
• Bevacizumab (Avastin)
• Aflibercept (VEGF-Trap, Zaltrap)
• Tyrosine Kinase Inhibitors
– New agents in clinical trials
• VEGF pathway
• Other antiangiogenic agents
![Page 60: Tumor angiogenesis - Columbia University › sites › default › files › JK2015pdf.pdf · Tumor angiogenesis Jan Kitajewski ICRC 926, ph 851-4688, email: jkk9. Blood Vessel Development](https://reader033.fdocuments.in/reader033/viewer/2022053011/5f0e80177e708231d43f8c1a/html5/thumbnails/60.jpg)
Bevacizumab and other tumor types
• Non-small cell lung adenocarcinoma
– E4559: OS 12.3 vs. 10.3 m in pts w/ chemo + bev
• Renal cell carcinoma
– AVOREN: PFS 10.2 vs. 5.4 m in pts w/ IFN +
bev;
• OS 2 month difference; attributed to crossover
• Glioblastoma multiforme
– AVF3708g: 2nd line, 9.2 m OS in bev alone arm Sandler A ,et al. NEJM. 2006; 355: 2542-50
Escudier B, et al. JCO 2010; 28:2144-50
Friedman HS, et al. JCO 2009; 27:4733-40
![Page 61: Tumor angiogenesis - Columbia University › sites › default › files › JK2015pdf.pdf · Tumor angiogenesis Jan Kitajewski ICRC 926, ph 851-4688, email: jkk9. Blood Vessel Development](https://reader033.fdocuments.in/reader033/viewer/2022053011/5f0e80177e708231d43f8c1a/html5/thumbnails/61.jpg)
![Page 62: Tumor angiogenesis - Columbia University › sites › default › files › JK2015pdf.pdf · Tumor angiogenesis Jan Kitajewski ICRC 926, ph 851-4688, email: jkk9. Blood Vessel Development](https://reader033.fdocuments.in/reader033/viewer/2022053011/5f0e80177e708231d43f8c1a/html5/thumbnails/62.jpg)
Bevacizumab side effects & cost • Common Side Effects:
– Hypertension (23-34%)
– Abdominal pain (50-61%), Constipation (29-40%)
– Asthenia (up to 70%), Headache (24-50%)
– Proteinuria (4-36%)
– Upper respiratory infection (40-47%)
• Serious Side Effects – Thromboemboli (9%), Neutropenia (21-27%)
– GI hemorrhage (19-24%), GI perforation (2.4%)
• Price in 2004: $2,750 per 400mg vial – One dose for 70kg pt (10mg/kg) = 2 vials ($5,500)
Thomsons Micromedex
Mayer R. NEJM. 2004; 350 (23): 2407-08
![Page 63: Tumor angiogenesis - Columbia University › sites › default › files › JK2015pdf.pdf · Tumor angiogenesis Jan Kitajewski ICRC 926, ph 851-4688, email: jkk9. Blood Vessel Development](https://reader033.fdocuments.in/reader033/viewer/2022053011/5f0e80177e708231d43f8c1a/html5/thumbnails/63.jpg)
Bevacizumab in Breast Cancer
• Feb 2008: FDA grants accelerated approval
– E2100: PFS 11.8 vs 5.9 (HR 0.6, P<0.001)
paclitaxel/bev vs paclitaxel alone in 1st line
– Accelerated approval program allows access to
promising new drugs while confirmatory trials
are conducted
Miller K, et al. NEJM 2007;357:2666-76.
![Page 64: Tumor angiogenesis - Columbia University › sites › default › files › JK2015pdf.pdf · Tumor angiogenesis Jan Kitajewski ICRC 926, ph 851-4688, email: jkk9. Blood Vessel Development](https://reader033.fdocuments.in/reader033/viewer/2022053011/5f0e80177e708231d43f8c1a/html5/thumbnails/64.jpg)
Non-VEGF Antiangiogenic Targets PlGF
Hicklin D J , et al. 2005
Yancopoulos et al. 2006
Radtke et al. 2005
![Page 65: Tumor angiogenesis - Columbia University › sites › default › files › JK2015pdf.pdf · Tumor angiogenesis Jan Kitajewski ICRC 926, ph 851-4688, email: jkk9. Blood Vessel Development](https://reader033.fdocuments.in/reader033/viewer/2022053011/5f0e80177e708231d43f8c1a/html5/thumbnails/65.jpg)
Ang/Tie Blockade
• AMG 386: First in class peptide-Fc peptibody
– Ovarian ca phase II in combo with chemo – median
PFS 7.2 vs 4.6 compared to pbo
– Phase III TRINOVA-1 enrolling
• MEDI3617: Ang1, Ang2 mAb
– 21 pts recruited; 4 continue (max response 6m)
– 5 had stabilization of dz for 3m or greater
• REGN910: Humanized Ang2 mAb
– Ongoing (NCT01271972) Karlan BY, et al. JCO 2012;30:362-71. Clinicaltrials.gov
Natale RB, et al. ASCO 2012 Abstract TPS2621
Papadopoulous KP et al. ASCO 2011 Abstract TPS159
![Page 66: Tumor angiogenesis - Columbia University › sites › default › files › JK2015pdf.pdf · Tumor angiogenesis Jan Kitajewski ICRC 926, ph 851-4688, email: jkk9. Blood Vessel Development](https://reader033.fdocuments.in/reader033/viewer/2022053011/5f0e80177e708231d43f8c1a/html5/thumbnails/66.jpg)
Notch Inhibition: GSI (nonspecific) – RO4929097:
• Phase I: Prolonged stable disease (3-6m) in 30 of 92 pts; esp in melanoma, sarcoma and ovarian carcinoma
• Toxicity: n/v/d, fatigue, low phosphate, skin rash
• Phase I/II trials now recruiting for glioblastoma, RCC, pancreatic cancer, CRC, breast cancer
– MK-0752:
• Phase I: 1 CR, 10 stable disease of 103 pts (most with brain tumors)
• Toxicity: n/v/d, fatigue, rash
• Phase I/II trials recruiting in breast, other advanced tumors
Tochler AW, et al. JCO 2012;30:2348-53.
Krop I, et al. JCO 2012;30:2307-13.
Clinicaltrials.gov
![Page 67: Tumor angiogenesis - Columbia University › sites › default › files › JK2015pdf.pdf · Tumor angiogenesis Jan Kitajewski ICRC 926, ph 851-4688, email: jkk9. Blood Vessel Development](https://reader033.fdocuments.in/reader033/viewer/2022053011/5f0e80177e708231d43f8c1a/html5/thumbnails/67.jpg)
Notch Inhibition
• Dll4 mAb:
– Demicizumab (OMP-21M18): humanized
• Pancreatic cancer: with gemcitabine
• NSCLC: with carboplatin and pemetrexed
– REGN421: fully human mAb
• Phase I in advanced malignancies
Clinicaltrials.gov
![Page 68: Tumor angiogenesis - Columbia University › sites › default › files › JK2015pdf.pdf · Tumor angiogenesis Jan Kitajewski ICRC 926, ph 851-4688, email: jkk9. Blood Vessel Development](https://reader033.fdocuments.in/reader033/viewer/2022053011/5f0e80177e708231d43f8c1a/html5/thumbnails/68.jpg)
![Page 69: Tumor angiogenesis - Columbia University › sites › default › files › JK2015pdf.pdf · Tumor angiogenesis Jan Kitajewski ICRC 926, ph 851-4688, email: jkk9. Blood Vessel Development](https://reader033.fdocuments.in/reader033/viewer/2022053011/5f0e80177e708231d43f8c1a/html5/thumbnails/69.jpg)